Corpus luteum follicle-stimulating hormone (FSH). A new corpus luteum develops with each menstrual cycle. The "corpus luteum" develops from an ovarian follicle during the luteal phase of the menstrual cycle or oestrous cycle, following the release of a secondary oocyte from the follicle during ovulation. The follicle first forms a corpus hemorrhagicum before it becomes a corpus luteum, but the term refers to the visible collection of blood, left after rupture of the follicle, that secretes progesterone. While the oocyte (later the zygote if fertilization occurs) traverses the Fallopian tube into the uterus, the corpus luteum remains in the ovary. The corpus
Topical progesterone of tissue exposure to progesterone with this route of administration. These findings provide a possible explanation for how some studies found antiproliferative and atrophic changes in the endometrium with topical progesterone. However, elevated levels of progesterone in the endometrium with topical progesterone have not yet been demonstrated. Concern has been raised regarding topical progesterone in that the effects of such supraphysiological levels of progesterone in tissues are unknown and hence the potential for harmful effects has not been ruled out. Salivary monitoring of progesterone levels in women using topical progesterone and adjustment of dosage as necessary has been suggested as